Evaluation of serum cystatin-C and symmetric dimethylarginine concentrations in dogs with heart failure from chronic mitral valvular insufficiency.

Reduction in glomerular filtration rate (GFR) is a common complication in advanced stages of heart failure (HF). The convenient and precise assessment for GFR would be useful for early detection of renal impairment in HF dogs. Our hypothesis of this study was the GFR would be reduced in advanced stages of HF from chronic mitral valvular insufficiency (CMVI), as indicated by renal markers including serum cystatin-C (Cys-C) and symmetric dimethylarginine (SDMA) concentrations. Forty-three client-owned dogs consisting of 33 dogs with different stages of HF from CMVI and 10 age-matched healthy dogs were enrolled in this study. Serum Cys-C and SDMA concentrations along with other renal (i.e., urea nitrogen and creatinine) and echocardiographic markers were evaluated in healthy and CMVI dogs. Serum Cys-C concentrations were 1.4 ± 0.4 mg/l in control, 2.1 ± 0.9 mg/l in ISACHC I, 2.9 ± 0.8 mg/l in ISACHC II and 3.6 ± 0.6 mg/l in ISACHC III dogs, whereas serum SDMA concentrations were 8 ± 2 µg/dl in control, 14 ± 3 µg/dl in ISACHC I, 18 ± 6 µg/dl in ISACHC II and 22 ± 7 µg/dl in ISACHC III dogs. There was close correlation of serum Cys-C and SDMA concentrations to serum creatinine, urea nitrogen and the severity of HF. Our study demonstrated that the GFR was decreased in dogs with CMVI having earlier stages of HF.

Evaluation of serum symmetric dimethylarginine in dogs with heartworm infection.

This study evaluated the circulating levels of serum symmetric dimethylarginine (SDMA) in 12 dogs with different severities of heartworm disease (HWD) and assessed the biochemical renal markers (blood urea nitrogen, creatinine). Dogs were classified into 2 groups based on the severity of clinical signs. Group A - asymptomatic to mild clinical signs, group B - moderate to severe clinical signs. The serum SDMA levels were higher in dogs in group B. Although the serum SDMA levels in dogs in group A were also higher than those of the control dogs, the difference was not statistically significant. There was a good correlation between renal markers and severity of clinical signs. This study demonstrated that the glomerular filtration rate was significantly decreased in dogs in group A; therefore, earlier detection of renal impairment is required for successful management of dogs with HWD.

La présente étude visait à évaluer les niveaux sériques de diméthylarginine symétrique (DMAS) chez 12 chiens atteints de maladie du vers du coeur (MVC) de différentes sévérités et d'examiner les marqueurs biochimiques rénaux (azote uréique sanguin, créatinine). Les chiens ont été classés en deux groupes sur la base de la sévérité des signes cliniques. Le Groupe A ­ asymptomatique à signes cliniques légers, groupe B ­ signes cliniques modérés à sévères. Les niveaux de DMAS sériques étaient plus élevés chez les chiens du groupe B. Chez les chiens du groupe A, bien que les niveaux sériques de DMAS étaient également plus élevés que ceux des chiens témoins, la différence n'était pas statistiquement significative. Il y avait une bonne corrélation entre les marqueurs rénaux et la sévérité des signes cliniques. Cette étude a permis de démontrer que le taux de filtration glomérulaire était diminué de manière significative chez les chiens du groupe A; ainsi, une détection précoce de déficience rénale est nécessaire pour la gestion réussie des chiens avec MVC.(Traduit par Docteur Serge Messier).